SUNDAY, SEPTEMBER 25, 2016

ACIP issues 2014 changes for immunization schedules

The U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recently issued its recommendations for immunizing individuals through the age of 18, according to the CDC.

The ACIP recommendations included several changes to the previous immunization schedules.

The legend for meningococcal conjugate vaccine row was updated to reflect recommendation for use of the MenACWY-CRM vaccine, also known as Menveo, as early as two months of age. According to the CDC, Menveo was approved by the U.S. Food and Drug Administration as part of a four-dose primary series in infants on August 1, 2013. The meningitis vaccine was previously approved for children and adults ages two through 55 years.

Footnotes for the meningococcal conjugate vaccine were updated to reflect recent recommendations for use of MCV4-CRM, another meningitis vaccine, in high-risk patients aged two months and older. Footnotes were also updated to provide pneumococcal vaccine guidance for vaccination of individuals with high-risk conditions and to provide guidance for hepatitis A vaccination in unvaccinated individuals at increased risk for infection.

The CDC published the changes in its journal the Morbidity and Mortality Weekly Report.

The immunization schedule provided in the report was approved by the ACIP, the American College of Obstetricians and Gynecologists and the American Academy of Family Physicians.